pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rybelsus · news · pharmadog
← back to Rybelsus
News mentioning Rybelsus
74
stories
1d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
2d
STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
stat
3d
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
stat
3d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
6d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
10d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
14d
Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor
fiercebiotech
15d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
15d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
22d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
22d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
28d
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
Oct 19, 26
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
Oct 15, 26
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
Oct 14, 26
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
Oct 14, 26
New study examines GLP-1 impact on interactions with criminal justice system, employment, housing stability
stat
Oct 2, 26
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
Oct 1, 26
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
Oct 1, 26
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
Sep 30, 26
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 24, 26
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
← prev
page 1 of 3
next →